Details for Patent: 8,642,012

Which drugs does patent 8,642,012 protect, and when does it expire?

Patent 8,642,012 protects RAVICTI and is included in one NDA.

This patent has forty patent family members in seventeen countries.

Summary for Patent: 8,642,012

Title:	Methods of treatment using ammonia-scavenging drugs
Abstract:	The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.
Inventor(s):	Scharschmidt; Bruce (South San Francisco, CA)
Assignee:	Hyperion Therapeutics, Inc. (South San Francisco, CA)
Application Number:	12/350,111
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,642,012
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,642,012

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Horizon Therap Us	RAVICTI	glycerol phenylbutyrate	LIQUID;ORAL	203284-001	Feb 1, 2013		RX	Yes	Yes						DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER

International Family Members for US Patent 8,642,012

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2735218
Canada	2735234
Cyprus	1118543